Good manufacturing practice for immunological veterinary medicinal products.
نویسنده
چکیده
Good manufacturing practice (GMP) is applied to the manufacture of immunological veterinary medicinal products (IVMPs) in a number of regions around the world. Within the European Union (EU) there are well-established requirements for GMP in the manufacture of IVMPs. Maintaining GMP when producing IVMPs is important because there are particular risks associated with their manufacture. These risks concern contamination and cross-contamination, environmental and operator protection, the variability of biological manufacturing processes and the limitations of some IVMP finished product tests. Whilst the general requirements of GMP are applicable to all medicinal products, guidance which addresses the specific concerns for IVMPs is provided by Annex 5 and also Annex 1 in Medicinal Products for Human and Veterinary Use: Good Manufacturing Practice (referred to as the GMP Guidelines). Extending and harmonising GMP requirements for IVMP manufacture throughout the world will increase the availability of high quality, safe and efficacious IVMPs.
منابع مشابه
DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Medicinal Products – Quality, Safety and Efficacy
Legal basis for publishing the detailed guidelines: Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal ...
متن کاملRegulation of immunological veterinary medicinal products in the European Union.
Since 1990, immunological veterinary medicinal products have been covered by the pharmaceutical legislation of the European Union (EU) and, as a consequence, these products are now subject to the relevant general provisions regarding manufacturing and marketing authorization. For new veterinary immunologicals, the legislation entered into force on 1 April 1993. For products already on the marke...
متن کاملRisk analysis in the manufacture of veterinary biologicals.
"Primum non nocere' must be the first quality of veterinary immunological medicinal products. Throughout the manufacturing process, stage by stage, various ingredients and/or operations could be responsible for safety problems observed when the product is administered. During the preliminary stages, various ingredients--e.g. master seed strains (virus, bacteria or parasite), cell substrates (ce...
متن کاملGood manufacturing practice: the role of local manufacturers and competent authorities.
In every country, a manufacturer of medicinal products for either human or veterinary use is required to operate in compliance with local legislation. In all EU Member States, legislation is approximated to the effect that they are committed to abide by the same standards. The candidate countries transpose the acquis into their national legislation, including the good manufacturing practice (GM...
متن کاملFrom discovery to approval of an advanced therapy medicinal product-containing stem cells, in the EU
In 1997, the human corneal epithelium was reconstructed in vitro and transplanted on patients. Later, it became a routine treatment, before regulations considered advanced therapy medicinal products and drugs on the same lines. Manufacturing, before and after good manufacturing practice setting, was established in different facilities and the clinical application in several hospitals. Advanced ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Revue scientifique et technique
دوره 26 1 شماره
صفحات -
تاریخ انتشار 2007